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Abstract
Multidrug-resistant (MDR) Mycobacterium tuberculosis complex (MTBC) strains represent a major threat for
tuberculosis (TB) control. Treatment of MDR-TB patients is long and less effective, resulting in a significant number
of treatment failures. The development of further resistances leads to extensively drug-resistant (XDR) variants.
However, data on the individual reasons for treatment failure, e.g. an induced mutational burst, and on the evolution
of bacteria in the patient are only sparsely available. To address this question, we investigated the intra-patient
evolution of serial MTBC isolates obtained from three MDR-TB patients undergoing longitudinal treatment, finally
leading to XDR-TB. Sequential isolates displayed identical IS6110 fingerprint patterns, suggesting the absence of
exogenous re-infection. We utilized whole genome sequencing (WGS) to screen for variations in three isolates from
Patient A and four isolates from Patient B and C, respectively. Acquired polymorphisms were subsequently validated
in up to 15 serial isolates by Sanger sequencing. We determined eight (Patient A) and nine (Patient B)
polymorphisms, which occurred in a stepwise manner during the course of the therapy and were linked to resistance
or a potential compensatory mechanism. For both patients, our analysis revealed the long-term co-existence of clonal
subpopulations that displayed different drug resistance allele combinations. Out of these, the most resistant clone
was fixed in the population. In contrast, baseline and follow-up isolates of Patient C were distinguished each by
eleven unique polymorphisms, indicating an exogenous re-infection with an XDR strain not detected by IS6110 RFLP
typing. Our study demonstrates that intra-patient microevolution of MDR-MTBC strains under longitudinal treatment is
more complex than previously anticipated. However, a mutator phenotype was not detected. The presence of
different subpopulations might confound phenotypic and molecular drug resistance tests. Furthermore, high
resolution WGS analysis is necessary to accurately detect exogenous re-infection as classical genotyping lacks
discriminatory power in high incidence settings.
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Introduction
Infection with strains of the Mycobacterium tuberculosis
complex (MTBC), the causative agent of tuberculosis (TB), is
responsible for approximately 1.4 million deaths annually [1].
Even more worrisome is the worldwide emergence of resistant,
multidrug-resistant (MDR), or extensively drug-resistant (XDR)
MTBC strains that pose a serious challenge for global TB
control and make successful treatment difficult or impossible
[1]. MDR strains are resistant to at least isoniazid (H) and
rifampicin (R), the most effective anti-TB first-line drugs. XDR is
defined as MDR with additional resistance to a fluoroquinolone,
e.g. levofloxacin (Lfx), moxifloxacin (Mfx), ofloxacin (Ofx), plus
resistance to any of the second-line injectable drugs
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capreomycin (Cm), amikacin (Am) or kanamycin (Km).
Recently, the WHO estimated 650.000 cases (including
150,000 deaths) of MDR-TB with an estimated XDR-TB rate of
9% in 2010 [1].
Drug resistant TB infection can be caused by transmission of
already resistant strains (primary resistance) or by selection of
resistance conferring mutations during inadequate therapy
(secondary resistance). Our own work [2] and a recent meta
analysis [3] indicated that the success of MDR treatment is low
in high incidence settings. Even during effective second-line
treatment, the development of additional resistances led to
XDR-TB in a significant number of cases. Transmission and
acquisition of drug resistance appear to depend on the genetic
background (phylogenetic lineage) of a strain population
circulating in a particular region. Different genetic backgrounds
might compensate for the fitness costs of acquired resistance
leading to more efficient transmission of resistant strains or to
rapid emergence of resistance in the course of the therapy due
to higher mutation rates [4,5]. This notion is strongly supported
by the fact that in areas with the highest proportions of MDR
strains (mainly in Eastern Europe), MDR-TB has been shown
to be strongly associated with infecting strains belonging to the
Beijing lineage of the MTBC [6–9].
Following earlier studies on the occurence of E.coli [10,11]
and P. aeruginosa [12] mutator phenotypes (with up to 1,000
fold increased mutation rates) in changing environmental
conditions, de Steenwinkel and colleagues hypothesized a
higher mutation rate for Beijing strains under antibiotic therapy.
The authors showed that Beijing genotype strains exhibit
significantly higher (1.6 × 10−5 to 5.4 × 10−3 versus 6.3 × 10−8 to
3.8 × 10−4, p = 0.003) mutation rates during experimental
rifampicin treatment compared to strains of the East African
Indian (EAI) lineage [5]. This observation was confirmed by
Ford et al. who reported a more rapid acquisition of drug
resistance in vitro for lineage 2 strains (comprising Beijing
isolates) compared to lineage 4 strains, although on a much
lower level [13]. While these studies pointed to a higher
mutation rate of lineage 2 strains that might explain an
enhanced resistance acquisition during standard therapy,
earlier studies using fluctuation assays did not show an
enhanced mutation capacity of Beijing strains [14].
Considering these controversial findings, direct investigations
of the genome evolution of clinical isolates in transmission
chains or in patients undergoing longitudinal therapy are
desirable. Recent studies applying Next Generation
Sequencing (NGS) technologies revealed that M. tuberculosis
genomes are highly stable during human to human
transmission and evolve with a mutation rate of approximately
0.5 single nucleotide polymorphisms (SNPs) per genome per
year [15,16]. So far, only two studies have used NGS to
analyze the genomes of serial isolates obtained from patients
during longitudinal treatment [17,18]. Saunders et al. 2011
determined a very low mutation rate in a non-Beijing strain
(personal communication) and concluded that its genome is
relatively stable within the host showing lower variability as
suggested by studies on emergence of drug resistance and
hypermutability [5,13]. However, Sun et al. showed for serial
isolates of three patients infected with Beijing strains that the
evolution in the patient might be more complex and the
population structure within a patient can be diverse [18]. The
authors identified 8-41 SNPs per sample, the majority of which
(82.7%) were only found at frequencies below 20%, including
four to five different resistance conferring variants [18]. This
might go in line with higher mutation rates of Beijing strains in
general leading to more complex evolutionary patterns and
faster acquisition of drug resistance. The authors also used
specific analysis tools to define low level variants (5%) that
explained a significant number of variations in their study.
To follow up on these findings, we investigated whether a
higher mutation rate is a general Beijing genotype
characteristic that holds true for Beijing strains from other areas
with high rates of MDR-TB. Therefore, we carried out whole
genome sequencing (WGS) of serial isolates derived from
three MDR-TB patients infected with Beijing strains undergoing
long-term treatment of up to 32 months. All isolates belonged
to the W-Beijing family and were closely related to strain types
that were described as successful MDR clones in
Karakalpakstan (Uzbekistan) [7], Kazakhstan [6], Turkmenistan
[7] and Abkhazia (Republic of Georgia) [8] (see Figure 1).
Special attention was given to the way mutations occurred, e.g.
in a stepwise manner related to the emergence of resistance to
additional drugs as suggested by Saunders and colleagues
[17], or by mutational burst during antibiotic treatment. A
transient or stable MTBC mutator phenotype, caused by higher
replication failure rates, might have substantially increased
mutation rates (10 to 1,000 fold increased) as indicated by
previous studies [5,10]. This in turn would co-select numerous
mutations, e.g. in non-coding regions and non-functional
mutations that hitchhike together with new resistance
mutations. To investigate this question we screened the




The three patients (A, B, C) were part of epidemiological
studies in Germany and Eastern Europe. Standardized
protocols for mycobacterial growth, DNA extraction, drug
susceptibility testing (DST), RFLP fingerprint, 24-loci MIRU-
VNTR and spoligotyping can be found in respective
publications (Patient A – Germany [19], Patient B – Abkhazia
(Republic of Georgia) [8,20], Patient C – Karakalpakstan
(Uzbekistan) [2]). DNA was isolated from subcultures grown on
Löwenstein-Jensen slants from sputum culture without single
colony passage to allow for investigation of the population
diversity within one isolate.
Identification of Polymorphisms
Genomic DNA of selected isolates was sequenced on
Illumina instruments at GATC Biotech (Konstanz, Germany).
For Patient A and C derived isolates we used 72 bp paired end
reads, and for Patient B 46 bp paired end reads, respectively.
Reads were mapped to the M. tuberculosis H37Rv genome
(GenBank ID: NC_000962.2) employing the exact alignment
program SARUMAN [21]. For all isolates, over 96% of the M.
Microevolution of MDR M.tb. Serial Isolates
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tuberculosis H37Rv genome was covered with at least one
read. Paired end reads from all analyzed isolates were
deposited in the NCBI sequence read archive (SRA) and can
be found under the accession number SRA060746.
Genomic regions featuring high GC content or repetitive
elements (e.g. PE/PPE/PGRS gene families, ESAT-6 like,
lppA, lppB, pks12) offer a serious challenge to WGS and data
analysis, which is often indicated by a low variant frequency
(<50%). To avoid the inclusion of false positives in our data set
and to detect the fixation of possible beneficial variants within
the population, we extracted polymorphisms from mapped
reads by in house Perl scripts using rather conservative quality
threshold levels, i.e. a minimum coverage of ten reads and a
minimum allele frequency of 75%. Detected polymorphisms of
all analyzed isolates were combined and majority nucleotides
for positions without a variant call were inferred from mapping
data (Table S7 in File S1). We screened serial patient derived
isolates subsequently for fixed mutations that occurred during
the treatment with at least 90% allele frequency and adjusted
coverage thresholds, and one outlier allowed. All
polymorphisms differentiating serial isolates and genes
associated with acquired drug resistances were further
validated by Sanger sequencing using an ABI3130xl
Sequencer. In addition, we applied VarDetect (vers.
200601251500) [22] to analyze peak height ratios of
heterogeneous SNPs in order to estimate the frequency of
different dominating subpopulations in all serial patient derived
isolates (see also Method S1).
Results
Based on our large in house database comprising IS6110
RFLP and spoligotyping patterns of MTBC strains analyzed in
previous studies, we selected three TB patients infected with
W-Beijing strains exhibiting a massive acquisition of additional
drug resistances during treatment, finally leading to XDR-TB. In
each case, exogenous re-infection was excluded in the
underlying study by identical IS6110 fingerprint patterns of the
serial isolates (Figure 1). The three patients have been enrolled
in studies performed in Germany [19], Abkhazia (Republic of
Georgia) [20], and Karakalpakstan (Uzbekistan) [2] .
Three isolates from Patient A and four isolates from Patient
B and C, respectively, covering the whole treatment period,
have been subjected to WGS. Obtained reads were processed
with our in house software pipeline described in Material and
Methods and Figure 2. SNPs and small deletions of
subpopulations predominating in selected isolates and genes
associated with resistance acquisition were further examined
by Sanger sequencing in up to 15 serial isolates and then
linked to the acquisition of phenotypic resistance to first and
second-line drugs. Furthermore, we applied VarDetect [22] to
calculate peak height ratios for heterogeneous SNPs and to
roughly estimate the nucleotide mixture and the frequency of
each subpopulation, respectively, in all patient derived isolates.
Intra-host genome evolution of Patient A and B isolates
was restricted to acquisition of drug resistance
conferring mutations
Patient A was dually infected with an H and streptomycin (S)
resistant non-Beijing strain and a MDR W-Beijing strain that
was resistant to H, R, S and ethambutol (E). The initial
treatment was effective against the non-Beijing strain but
inappropriate for the W-Beijing type strain. Outdated DST data
led to the development of resistance to six additional drugs
(including pyrazinamide (Z), prothionamide (Pto), PAS, Am,
Cm, Lfx) after clearance of the non-Beijing strain, resulting in a
“hyper-resistant” phenotype after 32 months of MDR-TB
treatment [19].
In comparison to H37Rv, we identified 1072 polymorphisms
by WGS, four of which were variable among the three selected
serial isolates, including a large deletion (3.1kb) in one isolate
(Table S1 in File S1). With respect to previously described drug
resistance associated mutations, all isolates had the following
variants: S315T in the gene katG known to confer resistance to
H [23], K43R in the gene rpsL shown to confer resistance to S
[24], and M306I in the gene embB linked with resistance to E
[25] (Table S1 in File S1). No SNP was present in the 81bp
“hot-spot” region of the gene rpoB ranging from codons
426-452 in H37Rv (GenBank ID: NC_000962.2), but all isolates
Figure 1.  Genotyping data of all analyzed patient derived isolates.  Unrooted UPGMA tree based on 289 concatenated single
nucleotide polymorphisms (SNPs) differentiating all analyzed W-Beijing isolates illustrated with corresponding IS6110 RFLP and 24-
loci MIRU-VNTR patterns. Vertical lines indicate patient derived isolates. Known resistance conferring SNPs were excluded.
doi: 10.1371/journal.pone.0082551.g001
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Figure 2.  Workflow.  Next generation sequencing (NGS) data
can be found under the accession number SRA060746. NGS
reads were mapped with SARUMAN (Blom et al. 2011) to the
H37Rv reference strain (GenBank ID: NC_000962.2). Variant
detection was carried out with in house Perl scripts, followed by
screening for high frequency polymorphisms that occurred
during treatment. Finally, we validated all detected
polymorphisms and genes associated with acquired
resistances in each patient with Sanger sequencing in all
available serial isolates.
doi: 10.1371/journal.pone.0082551.g002
carried the mutations V170F in rpoB and V483A, E1092D in
rpoC. The mutation V483A in rpoC has been described to
compensate for fitness costs of classical rpoB “hot-spot”
mutations causing resistance to R [26]. The mutation E1092D
in rpoC was also found in R susceptible Beijing strains [27],
thus most likely representing a phylogenetic rather than a
resistance causing variant. Hence, the mutation V170F in rpoB
is the most likely cause of resistance to R in this Beijing strain
that might have acquired enhanced virulence by the
compensatory mutation V483A in rpoC. All isolates exhibited
the nonsense mutation Q215* in the gene ethA
(monooxygenase) previously described to be involved in
resistance to Pto [28,29]. However, phenotypic resistance to
Pto was not detected till month 15 (Figure 3C) and coincided
with the mutation R59H in Rv0565c, encoding a putative
monooxygenase.
To further examine the exact course of genome evolution,
we analyzed the four detected polymorphisms differentiating
selected serial isolates and genes associated with resistance
acquisition to Z, Pto, PAS, Am, Cm, Lfx (pncA, ethA, thyA, rrs,
gyrA, respectively) by Sanger sequencing for eleven Patient A
derived isolates (Table S2 in File S1). This analysis revealed
additional heterogeneous SNPs indicating the simultaneous
presence and competition of three subpopulations (A1, A2 and
A3) emerging in Patient A and coinciding with resistance to Z
and Pto (Figure 3A). Nucleotide variants, characterizing each
subpopulation, were found for the genes pncA associated with
resistance to Z [24,30] and Rv0565c. The clone pncA L159V
(A1) was found in one patient derived isolate at month 15 only
(Figure 3A). In contrast, clones pncA T100P (A2) and pncA-
(A3), exhibiting a 3.1kb deletion affecting Rv2042 to Rv2045
(including pncA) in combination with R59H in Rv0565c, were
detected by PCR analysis until month 36 (Figure 3B). During
the course of the treatment, clones pncA- (A3) and pncA T100P
(A2) independently acquired the mutation 1401a>g in the gene
rrs conferring cross-resistance to Am and Cm [24,31].
Subsequently, 34 months after starting the treatment, clone
pncA T100P (A2) acquired either the mutation D94G or D94N
in the gene gyrA, while clone pncA- (A3) acquired the mutation
D94A in the gene gyrA (Figure 3A), all leading to resistance to
Lfx [24,32].
Patient B was initially enrolled in a prospective cross-
sectional study between 2003 and 2005, which targeted
determinants of drug-resistant tuberculosis in Abkhazia
(Republic of Georgia) [8,20]. The patient was integrated into
the study as non-MDR case, while the baseline isolate was
tested resistant to H, S and Km. During the course of first-line
antibiotic treatment (13 months) comprising a regimen of H, R,
E and Z, additional resistances to R and E were detected and
Patient B was classified as MDR case. According to the latest
DST results the treatment was changed to ethionamide (Eto),
Cm, Ofx, Cycloserine (Cs) and PAS (month 0 of MDR therapy).
During the course of another 21 months of MDR treatment, 15
serial isolates were obtained with alternating episodes of R, E,
Ofx, Eto resistant and susceptible isolates. All isolates were
initially tested susceptible to Cm, Cs and PAS, respectively.
Based on the sequencing results, DST was repeated for
selected isolates and we could confirm cross resistance
Microevolution of MDR M.tb. Serial Isolates
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between Km and Cm, as well as resistance acquisition to Cs
and PAS during treatment (Figure 4B).
WGS analysis identified 1575 polymorphisms compared to
H37Rv, six of which were variable among the four selected
Figure 3.  Evolution and competition of Patient A derived clones during MDR-TB therapy.  
* Isolates selected for whole genome sequencing (WGS).
† Isolate on month 15 was tested susceptible to ofloxacin, isolates on month 29 was tested susceptible to ciprofloxacin, isolate on
month 34 was tested resistant to levofloxacin.
§ Treatment efficacy is annotated as green=more than two effective drugs applied at the given time point, orange=two drugs being
active, red=only one drug active or treatment failure.
A) Model of intra-patient evolution and competition during 32 months of MDR-TB therapy of different W-Beijing subpopulations (A1,
A2, A3) in Patient A originating from the initial clone A0. Newly detected clones are colored in light blue. Peak height ratios
calculated by VarDetect [22] of corresponding chromatograms were used to estimate the frequency of predominating subpopulation
in all serial patient derived isolates. B) Multiplex-PCR analysis of Patient A derived isolates targeting a 3.1 kb deletion affecting
Rv2042 to Rv2045 (including pncA) showing a mixture of clones after 15 month of MDR-TB therapy. The larger fragment (593 bp)
represents the presence of that region; the 554 bp fragment is the product of primers flanking the large deletion. C) Resistogram of
phenotypic DST results. Red=resistant, green=susceptible, grey=no data. (A detailed description of genotypic and phenotypic drug
resistance acquisition of Patient A derived serial isolates, as well as applied regimens are presented in Table S2 in File S1).
doi: 10.1371/journal.pone.0082551.g003
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isolates (Table S3 in File S1). All isolates featured the mutation
katG (S315T) in combination with inhA (-15C>T) conferring
resistance to H [23] and low level resistance to Eto [33,34],
rpsL (K43R) conferring resistance to S [24], pncA (L151S)
associated with resistance to Z [24,30] and rrs (1401a>g)
conferring cross resistance to Km and Cm [24,31] respectively.
Furthermore, we found the mutation L452P in the “hot-spot”
region of rpoB that has been controversially described to be
associated with low level and high level resistance to R [35]
and the mutation G406D in the gene embB, shown to confer
resistance to E [36]. Drug resistance to E was not detected in
the first two isolates. However, resistance to E was found by
susceptibility testing of the following isolates.
Again we screened all Patient B derived serial isolates
(n=15) by Sanger sequencing for the six mutations identified in
selected specimens analyzed by WGS plus genes associated
with acquired resistance to R, E, Ofx, Eto, Cs, PAS (rpoB,
embB, gyrA, ethA, alr and thyA) (Table S4 in File S1).
Figure 4.  Evolution and competition of Patient B derived clones during MDR-TB therapy.  
* Isolates selected for whole genome sequencing (WGS).
§ Treatment efficacy is annotated as green=more than two effective drugs applied at the given time point, orange=two drugs being
active, red=only one drug active or treatment failure.
A) Model of intra-patient evolution and competition during 21 months of MDR-TB therapy of different W-Beijing subpopulations (B1,
B2, B2.1, B2.2) in Patient B originating from the initial clone B0. Newly detected clones are colored in light blue. Peak height ratios
calculated by VarDetect [22] of corresponding chromatograms were used to estimate the frequency of predominating subpopulation
in all serial patient derived isolates. B) Resistogram of phenotypic DST results. Red=resistant, green=susceptible, grey=no data. (A
detailed description of genotypic and phenotypic drug resistance acquisition of Patient B derived serial isolates, as well as applied
regimens are presented in Table S4 in File S1).
doi: 10.1371/journal.pone.0082551.g004
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Overall eight SNPs and one 1bp frameshift mutation
emerged during treatment in correlation with acquisition of
additional resistances and associated with the presence of five
subpopulations (B0, B1, B2, B2.1, B2.2). The subpopulations
were initially distinguished by different mutations in rpoB:
A435G (B1) and A584G (B2), both correlating with an R
resistant phenotype (Figure 4A, 4B). The MDR baseline R
susceptible clone (B0) could still be detected on month twelve
exhibiting no additional mutations. Clone rpoB A584G (B2) was
identified on month eight for the first time and later
independently acquired either the mutation D94Y (B2.1) or
D94G (B2.2), respectively, in gyrA conferring resistance to Ofx
[32]. The clone B2.1 exhibiting the combination rpoB A584G
and gyrA D94Y further acquired the mutation S22L in the gene
alr (Rv3423c, D-alanine racemase) on month eleven and was
the only clone found in isolates after 13 months of MDR-TB
therapy, thus outcompeting all other clones (Figure 4A).
Subsequently, clone B2.1 further acquired mutations in the
genes thyA (Rv2764c, thymidylate synthase), thyX (Rv2754c,
thymidylate synthase) and Rv1887 (hypothetical protein). The
mutation S22L in the gene alr coincided with a Cs resistant
phenotype, whereas a frame shift mutation in thyA was linked
with PAS resistance [37]. Interestingly, the disruption of the
thyA gene by a 1 bp deletion (A217fs) was linked with a
mutation in the upstream region of thyX (-3G>A). On month 20
of MDR therapy we detected another descendant of B2.1
carrying the mutations -19C>G upstream of thyX (instead of
-3G>A) in combination with Q245R in the gene Rv1887,
representing another clone possibly compensating for the loss
of ThyA (Figure 4A).
Whole Genome Sequencing Revealed an Exogenous
re-Infection with an XDR Strain in Patient C
Patient C was selected from an MDR-TB treatment cohort of
87 patients treated in Karakalpakstan (Uzbekistan). In the initial
study, we investigated the development of Ofx resistance and
extensively drug-resistant tuberculosis during MDR-TB
treatment and controlled for exogenous re-infection by IS6110
RFLP typing of the serial isolates obtained in case of treatment
failure [2].
The baseline isolate was tested phenotypically resistant to H,
R, S, Z and Pto. After eleven months of MDR-TB therapy, the
isolate (month 11) was also tested resistant to Ofx, Cm and
Am, thus classifying the isolate as XDR. On month 15 after
starting the treatment, the patient derived isolate was tested
resistant to E. The DST pattern was confirmed by a final isolate
four months later (Figure 5B). All four isolates exhibited the
same IS6110 and spoligotype pattern, as well as identical
mutations conferring resistance to H (katG S315N), E (embB
M306V), R (rpoB S450L) and S (rpsl K88R) (Figure 5A, Table
S5 in File S1), suggesting treatment failure with development of
resistance to four (respectively three, when considering the
possibility that isolates of month 0 and 11 could already have
been resistant to E) additional antibiotics during 15 months of
MDR-TB therapy.
In contrast to the findings in patients A and B showing a low
variability and stepwise acquisition of few SNPs over time, we
identified eight SNPs and three deletions unique to the initial
isolate and eleven SNPs unique to the following isolates
(Figure 5A, Table S5 and S6 in File S1), clearly separating the
latter three isolates (month 11-19) from the baseline isolate. All
three isolates obtained after month 11 exhibited no further
polymorphisms and had identical SNP profiles with known drug
resistance conferring mutations that coincided with an XDR
phenotype (Figure 5A, 5B), e.g. the mutation D94N in the gene
gyrA conferring resistance to Ofx [31,32], and the mutation
1401a>g in the gene rrs linked with Am and Cm cross
resistance [24,31].
Likewise, mutations associated with resistance to Z [24,30]
were different between baseline (pncA g.395_527del) and
Figure 5.  Exogenous re-infection with an XDR strain
observed in Patient C.  
* Isolate on month 11 was testest susceptible to ethambutol
(E), the following isolates on month 15 and 19 were tested
phenotypically resistant; all isolates exhibit the mutation embB
M306V.
A) Venn diagram showing that while the baseline isolate
(month 0) and follow up isolates (month 11-19) share common
drug resistance mutations and identical IS6110 RFLP
fingerprints (Figure 1) both are clearly differentiated by eleven
unique polymorphisms including additional drug resistance
conferring genes.
B) Resistogram of phenotypic DST results. Red=resistant,
green=susceptible.
doi: 10.1371/journal.pone.0082551.g005
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follow up isolates (pncA L120R), further contradicting an
evolutionary link between the latter isolates and the baseline
isolate (Figure 5A). Based on this data, we concluded that
Patient C was re-infected with an XDR strain exhibiting the
same IS6110 pattern as the first MDR strain that was
successfully treated by the applied MDR regimen [2]. This
notion was supported by MIRU-VNTR typing performed later
that revealed a difference in one out of 24 MIRU-VNTR loci
(Figure 1).
Discussion
In this study, we used WGS to determine the genome
evolution of W-Beijing strains under longitudinal MDR-TB
treatment of up to 32 months. Despite constant exposure to
antibiotic stress during the whole treatment period, we could
not find any indications for a burst of mutations e.g. by
induction of erroneous or loosened replication control in the
isolates investigated. Such a mutator type is expected to
acquire a considerable number of additional mutations, e.g.
non-functional mutations or intergenic mutations co-
segregating with new drug resistance conferring mutations.
However, nearly all mutations that were fixed in the population
had a clear association with drug resistance mechanisms and
occurred in a stepwise manner in strict correlation with the
acquisition of new phenotypic resistances (see Table 1). This
gradual acquisition of resistance conferring mutations and the
absence of hitchhiking mutations contradicts the hypothesis of
a stress induced mutational burst as proposed by others [5,38].
In line with previous studies [18,39,40], our data demonstrate
the longitudinal co-existence of different clonal subpopulations
within one patient. We observed a complex clonal population
structure with a variety of subpopulations displaying unique
resistance conferring mutation profiles as well as a different
composition of predominant subpopulations in distinct isolates
taken at the same time point. Target sequencing of up to 15
serial isolates of the whole treatment period extended these
findings and revealed the longitudinal parallel evolution of few
dominating clones within one patient. This intra-patient diversity
is likely to influence the performance of molecular and
phenotypic drug resistance tests and needs to be considered
for interpretation of routine diagnostic results [41,42]. New NGS
Table 1. Polymorphisms associated with drug resistance observed in this study.
Gene Positiona SNP Substitution Associated resistanceb In combination with Found in
gyrA 7,581 G>T D94Y FQ  Patient B
 7,581 G>A D94N   Patient A
 7,582 A>G D94G   Patient A, B
 7,582 A>C D94A   Patient A
rpoB 760,314 G>T V170F R rpoC V483A Patient A
 761,110 A>G A435G  rpoB L452P Patient B
 761,155 C>T S450L  rpoC H525N Patient C
 761,557 C>G A584G  rpoB L452P Patient B
rpsL 781,687 A>G K43R S  Patient A, B
 781,822 A>G K88R   Patient C
rrs 1,473,246 a>g 1401 Km/Am/Cm  Patient A, B, C
katG 2,155,168 C>G S315T H  Patient A
 2,155,168 C>G S315T H fabG1/inhA -15C>T Patient B
 2,155,168 C>T S315N   Patient C
pncA 2,288,767 G>C L159V Z  Patient A
 2,288,790 A>G L151S   Patient B
 2,288,883 A>C L120R   Patient C
 2,288,944 T>G T100P   Patient A
   g.395_527del   Patient C
   Rv2042c_Rv2045cdel   Patient A
eis 2,715,342 C>T -10 Km  Patient C
thyA 3,073,821 delG A217fs PAS thyX -19C>G, -3G>A Patient B
alr 3,841,356 G>A S22L Cs  Patient B
embB 4,247,429 A>G M306V E  Patient C
 4,247,431 G>C M306I   Patient A
 4,247,730 G>A G406D   Patient B
ethA 4,326,831 G>A Q215* Pto/Eto Rv0565c R59H Patient A
 4,326,452 G>T A341E   Patient C
a H37Rv genome (GenBank ID: NC_000962.2)
b FQ=fluoroquinolones, R=rifampicin, S=streptomycin, Km=kanamycin, Cm=capreomycin, H=isoniazid, Z=pyrazinamide, PAS=para-aminosalicylic acid, Cs=cycloserine,
E=ethambutol, Eto=ethionamide, Pto=prothionamide
doi: 10.1371/journal.pone.0082551.t001
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based diagnostic algorithms need to consider that the presence
of mixed populations in MDR-TB patients might be the normal
situation rather than the exception, which poses special
challenges for NGS based resistance diagnostics as those
algorithms must be optimized to unravel distinct
subpopulations.
The intra-patient evolution observed in patients A and B was
characterized by several phases of ineffective drug regimens
during which clonal competition drove the selection towards
highly resistant phenotypes that outcompeted the less resistant
or less fit variants. This evolutionary process led to the
acquisition of additional resistance mutations and/or possible
compensatory mutations, e.g. as found in the upstream region
of thyX (-19C>G, -3G>A) in PAS resistant isolates in Patient B.
Importantly, these mixed populations not only comprised
compositions of susceptible and resistant alleles that might be
expected when resistant cells are selected and replace
susceptible ancestors, but they also demonstrated the parallel
selection and evolution of different resistant subpopulations.
This underlines the ability of MTBC strains to adapt and evolve
within the patient. However, more studies are necessary to
answer the intriguing question of how the phylogenetic
background of clinical isolates can influence treatment
outcome.
Our data demonstrated that second-line drugs used for
treatment are indeed acting on MDR strains by exerting an
evolutionary pressure that selects for drug resistance
conferring mutations. For the first-line drug rifampicin, one
interesting question is the importance of mutations outside the
rpoB “hot-spot” region (codons 426-452, H37Rv annotation),
which is usually interrogated by molecular resistance assays,
for the development of resistance. For Patient B, our data
indicated a stepwise acquisition of resistance to rifampicin that
involved the initial acquisition of a probable low level resistance
mutation (rpoB L452P) [35], followed by additional rpoB
mutations: A435G (low level resistance) [43] and A584G (not
reported so far), which finally conferred high level resistance to
rifampicin. Furthermore, we found a yet unknown mutation
V170F in the gene rpoB, in combination with the mutation
V483A in the gene rpoC, suggested to be a potential
compensatory mutation [26], which might explain the
transmissibility of the MDR strain that infected Patient A [19].
Molecular mechanisms for the oral bacteriostatic second-line
drugs PAS and Cs are only partly understood [24]. A previous
study suggested that mutations in the gene thyA play a role in
resistance development to PAS [37]. We could link a frameshift
mutation in thyA (A217fs) to the emergence of PAS resistance
in Patient B. This is in line with a recent report demonstrating
that the absence of functional ThyA confers resistance to PAS
[44]. Interestingly, mutations in the upstream region of thyX
(-19C>G, -3G>A) emerged in the ThyA defective isolates. We
suggest that these potential thyX promoter mutations
compensate for the likely loss of function of ThyA. This notion
is supported by findings determined in a recent study from
Fivian-Hughes et al. [44]. The authors showed that ThyA and
ThyX are different unrelated types of thymidylate (dTMP)
synthases; while deletion of thyA conferred resistance to PAS,
ThyX most likely compensated the loss of ThyA with a low
dTMP synthase activity [44]. Thus, up-regulation of ThyX might
represent an important compensatory mechanism contributing
to fitness levels of PAS resistant strains.
Furthermore, our analysis linked resistance to cycloserine to
mutations in the gene alr (S22L). This is in line with reports
suggesting the mycobacterial alanine racemase (Alr) as target
for Cs [24,45] and overexpression experiments of the D-alanine
racemase that led to Cs resistance in Mycobacterium
smegmatis [46]. Cross resistance to the prodrugs ethionamide
(Eto) and prothionamide (Pto) was suggested to be mediated
by alterations in the gene ethA (monooxygenase) [28] or by up-
regulation of the target protein InhA [33,34]. The data obtained
for Patient A isolates let us assume that the disruption (Q215*)
of ethA alone did not confer resistance to Pto. As suggested
previously [29], the activation of Eto and Pto may include
additional enzymes. Here, our data indicated the involvement
of the acquired mutation R59H in the putative monooxygenase
Rv0565c that coincided with resistance acquisition to Pto
(Figure 3A, 3B). Ambiguous DST results for Eto in Patient B
derived isolates are most likely the result of low level resistance
conferred by the mutation fabG1/inhA -15 C>T.
We are confident that we identified an exogenous re-
infection of a MDR patient with an XDR strain indistinguishable
by IS6110 fingerprint patterns and with identical resistance
mutations to four first-line drugs. However, a mixed infection at
baseline cannot be completely ruled out by the data obtained in
the study. The XDR clone might have been absent in the
baseline specimen by chance or only been present at very low
frequency (not detectable by the applied 1% proportion method
for DST). Importantly, we can exclude the clonal relatedness of
both strains, and thereby highlight the risk of XDR-TB
transmission in high incidence MDR-TB regions. Recent
studies applying WGS on outbreak isolates defined the
expected variations between clinical isolates from confirmed
transmission chains to a maximum of five SNPs [15,16]. In
contrast, baseline and latter isolates obtained from Patient C
were distinguished each by eleven unique polymorphisms, and
also displayed a single locus variant in the 24-loci MIRU-VNTR
patterns. Early WGS based analysis of the genomes of closely
related Beijing isolates already demonstrated that standard
genotyping methods obviously lack discriminatory power. This
makes the interpretation of molecular epidemiological studies
on isolates from Eastern European high incidence settings,
applying only such markers, rather difficult [47]. These
observations have clear consequences for the interpretation of
molecular epidemiological studies especially in high incidence
areas and suggest that the analysis of ongoing transmission by
standard molecular epidemiological techniques may establish
false links between patients. This might lead to an
overestimation of ongoing MTBC transmission and
underestimation of the complexity of the pathogen population
[47].
Conclusion
Our results showed that the intra-patient evolution of W-
Beijing strains was characterized by a stepwise acquisition of
resistance conferring mutations selecting for the most resistant
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phenotype during inadequate MDR-TB therapy. This
incremental process without an accumulation of mutations
hitchhiking with prominent resistance-associated mutations
does not support the hypothesis of a stress induced mutational
burst. However, the evolution of MTBC strains within the
patient during drug treatment can be complex and mixtures of
susceptible and resistant subpopulations as well as mixtures of
subpopulations with different resistance conferring mutations
can co-exist over long time periods. This diversity gives rise to
MTBC strains which can adapt and evolve within the patient
and therefore underlines the importance of a correct
identification of mixed infections and treatment failures, arguing
strongly for the application of genome based molecular
epidemiology.
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